Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

A Forward Look, the Year Ahead - Research Report on CBS Corporation, Comcast Corporation, Gilead Sciences Inc., Celgene



 A Forward Look, the Year Ahead - Research Report on CBS Corporation, Comcast
  Corporation, Gilead Sciences Inc., Celgene Corporation and Kellogg Company

PR Newswire

NEW YORK, February 20, 2013

NEW YORK, February 20, 2013 /PRNewswire/ --

Today, National Traders Association announced new research reports
highlighting CBS Corporation (NYSE:CBS), Comcast Corporation (NASDAQ:CMCSA),
Gilead Sciences Inc. (NASDAQ:GILD), Celgene Corporation (NASDAQ:CELG) and
Kellogg Company (NYSE:K). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

CBS Corporation Research Report

The great joy of earning better-than-expected revenues is evident for the
Super Bowl ad time which CBS and its stakeholders are very much looking
forward to. Analysts are expecting CBS to generate somewhere between $250
million to $300 million just for Super Bowl ad sales. Considering the large
audience of the Super Bowl, someone always has to pay higher than usual. But,
the big catch is the local ad sales which produce about 85% profit margin for
the company. By all means, for a company that relies on ad sales, it may
always be reasonable to pursue a case against someone deliberately taking away
your profits from you - even if it means allocating a budget for litigation.
The Full Research Report on CBS Corporation - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
[http://www.nationaltradersassociation.org/r/entire_report/5552_CBS]

Comcast Corporation Research Report

While it's high-time for Super Bowl and the growing business of
advertisements, Comcast may also be earning better-than-expected revenues
because of strong ad sales. Although ad sales are always worth the buzz,
Comcast seems to be busy creating a series of waves that will mark another
milestone for the company. Xfinity is Comcast's most recent premier project.
Xfinity is a premier Internet destination that targets the African American
community, in celebration of its culture, heritage and contributions to the
global community. From US President Barack Obama to The Jackson 5, Comcast's
Xfinity is worth the watch. The Full Research Report on Comcast Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.nationaltradersassociation.org/r/entire_report/fa2b_CMCSA]

Gilead Sciences Inc. Research Report

Gilead has been getting the attention of analysts, investors, medical
professionals and patients who have found hope in the world's largest maker of
HIV drugs. During the last week of August 2012, the company launched the HIV
drug Stribilid, or the "quad," which is a combination of four different
medicines. Although the drug only had a few weeks of sales during Q3, the
figures seem to be picking up.  While sales of HIV drugs are continuing to
increase, analysts and investors have other reasons to be bullish about the
company. Gilead's acquisition of Pharmasset Inc., along with its highly
coveted Sofusbivir hepatitis C drug, may help the company generate an
additional $3.8 billion by 2020. The company is also investing on blood cancer
drugs, and has reportedly spent $1.2 billion on blood cancer drugs. Gilead is
still looking at great potentials to expand its offerings, and it is targeting
to meet the significantly growing market demand for blood cancer treatments.
The Full Research Report on Gilead Sciences Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
[http://www.nationaltradersassociation.org/r/entire_report/6e69_GILD]

Celgene Corporation Research Report

Celgene's executives and stakeholders are delighted to celebrate a 14%
increase in net product sales during Q4. Celgene's full year adjusted net
income for 2012 reached $2.1 billion, a solid growth performance that accounts
for the company's global market share. Celgene's net product sales for
Abraxane and Vidaza saw a 3% increase, and a remarkable 17% increase for
Revlimid. Celgene's Revlimid is probably one of its products which have been
helping the company maintain its solid performance. Some analysts say that
Celgene is still a good buy because of the catalysts that will drive the
company to its $12 billion annual revenue by 2017. The most important factor
that investors must focus on is each company's portfolio. The Full Research
Report on Celgene Corporation - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.nationaltradersassociation.org/r/entire_report/5e17_CELG]

Kellogg Company Research Report

Kellogg, best known for its ready-to-eat cereals, has since expanded to
produce more food items like cookies, crackers, and potato chips, among others
partly through its many acquisitions in the past. Its most recent purchase,
Pringles, put the company in second place in the savory snack market behind
Lays and Doritos maker PepsiCo. Motley Fool says both Kellogg and PepsiCo
should benefit from rising income and increased urbanization outside the US,
as demand for convenient pre-packaged food is likely to increase
exponentially. In addition, Kellogg forged another deal for international
growth with Singapore-based Wilmar International, which will manufacture,
sell, and distribute Kellogg's brands in China. However, Zacks maintains its
"neutral" rating on the company despite robust numbers, citing sluggish sales
on its legacy cereals business and declines in its European business.
Nevertheless, Kellogg's brand positioning, geographic diversity, cost-cutting,
and the Pringles acquisition should counter these negatives. The Full Research
Report on Kellogg Company - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.nationaltradersassociation.org/r/entire_report/ac51_K]

Consider National Traders Association

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Demi Lapierre
Email: press@NationalTradersAssociation.org
Main: +1-(702)-212-4493

SOURCE National Traders Association
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement